ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Exscientia, a British provider of artificial intelligence for drug discovery with its own drug pipeline, will acquire Allcyte, an Austrian developer of AI applications for precision medicine, for about $60 million. Exscientia says the purchase will add the ability to perform high-content evaluation of individual patient biology in primary tumor tissues rather than in artificial cell lines or animal models, allowing integrated drug discovery and patient selection. Exscientia plans to expand Allcyte’s facility in Vienna.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter